-
Je něco špatně v tomto záznamu ?
Metformin directly targets the H3K27me3 demethylase KDM6A/UTX
E. Cuyàs, S. Verdura, L. Llorach-Pares, S. Fernández-Arroyo, F. Luciano-Mateo, N. Cabré, J. Stursa, L. Werner, B. Martin-Castillo, B. Viollet, J. Neuzil, J. Joven, A. Nonell-Canals, M. Sanchez-Martinez, JA. Menendez,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
SAF2016-80639-P
Ministerio de Ciencia e Innovación - International
Plan Nacional de I+D+I, Spain - International
2014 SGR229
Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) - International
Departament d'Economia i Coneixement, Catalonia, Spain - International
16-31604A
Czech Health Council Foundation - International
CD15/00033
Ministerio de Sanidad y Consumo - International
Fondo de Investigación Sanitaria (FIS), Spain - International
Roche Pharma (Spain) - International
Astellas Pharma (Spain) - International
Armangué family (Girona, Catalonia) to the Metabolism and Cancer Group (Girona Biomedical Research Institute) - International
NV16-31604A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
NLK
Directory of Open Access Journals
od 2014
Free Medical Journals
od 2002 do Před 2 roky
PubMed Central
od 2008
Open Access Digital Library
od 2002-01-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2014-01-01
Medline Complete (EBSCOhost)
od 2003-02-01
Wiley-Blackwell Open Access Titles
od 2002
ROAD: Directory of Open Access Scholarly Resources
od 2002
PubMed
29740925
DOI
10.1111/acel.12772
Knihovny.cz E-zdroje
- MeSH
- biokatalýza MeSH
- experimentální nádory farmakoterapie metabolismus MeSH
- histondemethylasy antagonisté a inhibitory metabolismus MeSH
- inhibitory enzymů chemie farmakologie MeSH
- jaderné proteiny antagonisté a inhibitory metabolismus MeSH
- lidé MeSH
- ligandy MeSH
- metformin chemie farmakologie MeSH
- molekulární modely MeSH
- molekulární struktura MeSH
- myši knockoutované MeSH
- myši MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Metformin, the first drug chosen to be tested in a clinical trial aimed to target the biology of aging per se, has been clinically exploited for decades in the absence of a complete understanding of its therapeutic targets or chemical determinants. We here outline a systematic chemoinformatics approach to computationally predict biomolecular targets of metformin. Using several structure- and ligand-based software tools and reference databases containing 1,300,000 chemical compounds and more than 9,000 binding sites protein cavities, we identified 41 putative metformin targets including several epigenetic modifiers such as the member of the H3K27me3-specific demethylase subfamily, KDM6A/UTX. AlphaScreen and AlphaLISA assays confirmed the ability of metformin to inhibit the demethylation activity of purified KDM6A/UTX enzyme. Structural studies revealed that metformin might occupy the same set of residues involved in H3K27me3 binding and demethylation within the catalytic pocket of KDM6A/UTX. Millimolar metformin augmented global levels of H3K27me3 in cultured cells, including reversion of global loss of H3K27me3 occurring in premature aging syndromes, irrespective of mitochondrial complex I or AMPK. Pharmacological doses of metformin in drinking water or intraperitoneal injection significantly elevated the global levels of H3K27me3 in the hepatic tissue of low-density lipoprotein receptor-deficient mice and in the tumor tissues of highly aggressive breast cancer xenograft-bearing mice. Moreover, nondiabetic breast cancer patients receiving oral metformin in addition to standard therapy presented an elevated level of circulating H3K27me3. Our biocomputational approach coupled to experimental validation reveals that metformin might directly regulate the biological machinery of aging by targeting core chromatin modifiers of the epigenome.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19045465
- 003
- CZ-PrNML
- 005
- 20200113082240.0
- 007
- ta
- 008
- 200109s2018 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/acel.12772 $2 doi
- 035 __
- $a (PubMed)29740925
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Cuyàs, Elisabet $u ProCURE (Program Against Cancer Therapeutic Resistance), Metabolism & Cancer Group, Catalan Institute of Oncology, Girona, Catalonia, Spain. Girona Biomedical Research Institute (IDIBGI), Girona, Spain.
- 245 10
- $a Metformin directly targets the H3K27me3 demethylase KDM6A/UTX / $c E. Cuyàs, S. Verdura, L. Llorach-Pares, S. Fernández-Arroyo, F. Luciano-Mateo, N. Cabré, J. Stursa, L. Werner, B. Martin-Castillo, B. Viollet, J. Neuzil, J. Joven, A. Nonell-Canals, M. Sanchez-Martinez, JA. Menendez,
- 520 9_
- $a Metformin, the first drug chosen to be tested in a clinical trial aimed to target the biology of aging per se, has been clinically exploited for decades in the absence of a complete understanding of its therapeutic targets or chemical determinants. We here outline a systematic chemoinformatics approach to computationally predict biomolecular targets of metformin. Using several structure- and ligand-based software tools and reference databases containing 1,300,000 chemical compounds and more than 9,000 binding sites protein cavities, we identified 41 putative metformin targets including several epigenetic modifiers such as the member of the H3K27me3-specific demethylase subfamily, KDM6A/UTX. AlphaScreen and AlphaLISA assays confirmed the ability of metformin to inhibit the demethylation activity of purified KDM6A/UTX enzyme. Structural studies revealed that metformin might occupy the same set of residues involved in H3K27me3 binding and demethylation within the catalytic pocket of KDM6A/UTX. Millimolar metformin augmented global levels of H3K27me3 in cultured cells, including reversion of global loss of H3K27me3 occurring in premature aging syndromes, irrespective of mitochondrial complex I or AMPK. Pharmacological doses of metformin in drinking water or intraperitoneal injection significantly elevated the global levels of H3K27me3 in the hepatic tissue of low-density lipoprotein receptor-deficient mice and in the tumor tissues of highly aggressive breast cancer xenograft-bearing mice. Moreover, nondiabetic breast cancer patients receiving oral metformin in addition to standard therapy presented an elevated level of circulating H3K27me3. Our biocomputational approach coupled to experimental validation reveals that metformin might directly regulate the biological machinery of aging by targeting core chromatin modifiers of the epigenome.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a biokatalýza $7 D055162
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a inhibitory enzymů $x chemie $x farmakologie $7 D004791
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a histondemethylasy $x antagonisté a inhibitory $x metabolismus $7 D056466
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ligandy $7 D008024
- 650 _2
- $a metformin $x chemie $x farmakologie $7 D008687
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši knockoutované $7 D018345
- 650 _2
- $a molekulární modely $7 D008958
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a experimentální nádory $x farmakoterapie $x metabolismus $7 D009374
- 650 _2
- $a jaderné proteiny $x antagonisté a inhibitory $x metabolismus $7 D009687
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Verdura, Sara $u ProCURE (Program Against Cancer Therapeutic Resistance), Metabolism & Cancer Group, Catalan Institute of Oncology, Girona, Catalonia, Spain. Girona Biomedical Research Institute (IDIBGI), Girona, Spain.
- 700 1_
- $a Llorach-Pares, Laura $u Mind the Byte, Barcelona, Spain.
- 700 1_
- $a Fernández-Arroyo, Salvador $u Unitat de Recerca Biomèdica, Hospital Universitari de Sant Joan, IISPV, Rovira i Virgili University, Reus, Spain.
- 700 1_
- $a Luciano-Mateo, Fedra $u Unitat de Recerca Biomèdica, Hospital Universitari de Sant Joan, IISPV, Rovira i Virgili University, Reus, Spain.
- 700 1_
- $a Cabré, Noemí $u Unitat de Recerca Biomèdica, Hospital Universitari de Sant Joan, IISPV, Rovira i Virgili University, Reus, Spain.
- 700 1_
- $a Stursa, Jan $u Institute of Chemical Technology, Prague, Czech Republic. Institute of Biotechnology, Czech Academy of Sciences, Prague-West, Czech Republic.
- 700 1_
- $a Werner, Lukas $u Institute of Chemical Technology, Prague, Czech Republic. Institute of Biotechnology, Czech Academy of Sciences, Prague-West, Czech Republic.
- 700 1_
- $a Martin-Castillo, Begoña $u Unit of Clinical Research, Catalan Institute of Oncology, Girona, Spain.
- 700 1_
- $a Viollet, Benoit $u INSERM U1016, Institut Cochin, Paris, France. CNRS UMR 8104, Paris, France. Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
- 700 1_
- $a Neuzil, Jiri $u Institute of Biotechnology, Czech Academy of Sciences, Prague-West, Czech Republic. School of Medical Science, Menzies Health Institute Queensland, Griffith University, Southport, Queensland, Australia.
- 700 1_
- $a Joven, Jorge $u Unitat de Recerca Biomèdica, Hospital Universitari de Sant Joan, IISPV, Rovira i Virgili University, Reus, Spain.
- 700 1_
- $a Nonell-Canals, Alfons $u Mind the Byte, Barcelona, Spain.
- 700 1_
- $a Sanchez-Martinez, Melchor $u Mind the Byte, Barcelona, Spain.
- 700 1_
- $a Menendez, Javier A $u ProCURE (Program Against Cancer Therapeutic Resistance), Metabolism & Cancer Group, Catalan Institute of Oncology, Girona, Catalonia, Spain. Girona Biomedical Research Institute (IDIBGI), Girona, Spain.
- 773 0_
- $w MED00007638 $t Aging cell $x 1474-9726 $g Roč. 17, č. 4 (2018), s. e12772
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29740925 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20200113082612 $b ABA008
- 999 __
- $a ok $b bmc $g 1483734 $s 1084138
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 17 $c 4 $d e12772 $e 20180508 $i 1474-9726 $m Aging cell $n Aging cell $x MED00007638
- GRA __
- $a SAF2016-80639-P $p Ministerio de Ciencia e Innovación $2 International
- GRA __
- $p Plan Nacional de I+D+I, Spain $2 International
- GRA __
- $a 2014 SGR229 $p Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) $2 International
- GRA __
- $p Departament d'Economia i Coneixement, Catalonia, Spain $2 International
- GRA __
- $a 16-31604A $p Czech Health Council Foundation $2 International
- GRA __
- $a CD15/00033 $p Ministerio de Sanidad y Consumo $2 International
- GRA __
- $p Fondo de Investigación Sanitaria (FIS), Spain $2 International
- GRA __
- $p Roche Pharma (Spain) $2 International
- GRA __
- $p Astellas Pharma (Spain) $2 International
- GRA __
- $p Armangué family (Girona, Catalonia) to the Metabolism and Cancer Group (Girona Biomedical Research Institute) $2 International
- GRA __
- $a NV16-31604A $p MZ0
- LZP __
- $a Pubmed-20200109